Autolus Notice of Annual General Meeting (AGM) on Friday, June 18, 2021
May 21 2021 - 7:00AM
Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage
biopharmaceutical company developing next-generation programmed T
cell therapies, today posted notice of its Annual General Meeting
(AGM) to shareholders (the "Notice"), which can be viewed and
downloaded from www.autolus.com. The Notice states that the
AGM is scheduled to be held at Autolus headquarters in White City
at 1.00 pm BST (8.00 am EDT) on Friday, June 18, 2021.
At present, measures restricting movement and
gatherings are in force in England to address the spread of
COVID-19. Among other things, these measures prohibit persons from
participating in gatherings consisting of six or more people in any
indoor space (“COVID-19 Measures”). The UK government has indicated
in its “roadmap” that these restrictions will still be in place by
the time of our AGM. Accordingly, the Company and its shareholders
are required to comply with these measures in holding the AGM.
In order to ensure that our AGM may proceed on
Friday, 18 June 2021 in compliance with the COVID-19 Measures,
arrangements have been made for a quorum of two shareholders only
to be present at our AGM this year. On this basis, the Board has
concluded that as long as the COVID-19 Measures remain in force,
shareholders must not attend the AGM in person this year and,
instead, should submit proxy votes as described below. In
compliance with the COVID-19 Measures, it is expected that no
members of the Board will attend the AGM in person.
Arrangements for the 2021
AGMThe AGM will be convened at the address set out in the
Notice with the minimum required quorum of two shareholders present
in order to conduct the business of the meeting. The results of the
poll votes on the proposed resolutions will be announced, in the
usual way, via a press release, as soon as practicable after the
conclusion of the AGM. Given the meeting format changes, and the
need to keep the people present to a minimum, no webcast will be
provided.
VotingIt is as important as
ever that shareholders cast their votes in respect of the business
of the AGM. This year, if you want your vote to count, you must
vote ahead of the meeting as it will not be possible to do so
during the AGM. Any advance voting must be done by completing a
proxy form, submitting proxy instructions electronically or casting
your votes through the medium attributable to the way that you hold
your shares. We strongly encourage you to vote as early as
possible.
If appointing a proxy, shareholders are strongly
encouraged to appoint the "Chair of the meeting" to ensure their
appointed proxy is present and can vote on their behalf.
About Autolus Therapeutics
plcAutolus is a clinical-stage biopharmaceutical company
developing next-generation, programmed T cell therapies for the
treatment of cancer. Using a broad suite of proprietary and modular
T cell programming technologies, the company is engineering
precisely targeted, controlled and highly active T cell therapies
that are designed to better recognize cancer cells, break down
their defense mechanisms and eliminate these cells. Autolus has a
pipeline of product candidates in development for the treatment of
hematological malignancies and solid tumors. For more information,
please visit www.autolus.com.
Contact:
Julia Wilson+44 (0) 7818
430877j.wilson@autolus.com
Susan A. NoonanS.A. Noonan
Communications+1-212-966-3650susan@sanoonan.com
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Apr 2023 to Apr 2024